Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Key Points. Axicabtagene ciloleucel induced long-term survival with no new safety signals in patients with refractory LBCL.Durable responses were associated wit

  • 123456 Profile photo of Madelyn

    While we await the overall survival data for ZUMA-7, the mature ZUMA-1 data shows the curative potential of Axi-cel (Yescarta) for relapsed/refractory DLBCL.

    Takeaway from TFOC:
    – Best response CR in 59% –> many will still relapse!
    – Long term CR in 30% –> CURE!